TABLE 1

Characteristics of study patients

Sarcoidosis (n=76)
Age at time of biopsy years43.98±12.22
Male sex42 (55)
Ever smoker43 (59)
White64 (84)
Medication at time of biopsy6 (8)
Third-line therapy#27 (36)
COS group A/B (2 years follow-up)23/49 (32/68)
COS group A/B (5 years follow-up)15/31 (33/67)
Scadding stage at time biopsy (0/I/II/III/IV/unknown)5/19/28/9/10/5 (7/25/37/12/13/7)
Extrapulmonary involvement54 (71)
 Skin18 (24)
 Eyes7 (9)
 Liver8 (11)
 Heart13 (17)
 Spleen3 (4)
 Bones4 (5)
 Nerve system15 (20)
  Central6 (8)
  Peripheral1 (1)
  Small fibre neuropathy10 (13)

Data are presented as mean±sd or n (%). Scadding stages: 0: normal chest radiograph; I: BHL; II: BHL with pulmonary infiltrates; III: pulmonary infiltrates without BHL; IV: fibrosis. COS: clinical outcome status. #: third-line therapy consisted of infliximab use at follow-up.